Skip to main content
HCPCS Q5148 · Level II · Part B drug

Q5148: filgrastim-txid (Nypozi), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q5148

Billing unit
1 MCG
Inj, nyposi 1 mcg
ASP payment limit
$1.026
October 2026; -0.8% vs July 2026
Practitioner MUE
1500
MAI 3
OPPS status
SI G
APC 0811
NCCI exposure
no PTP pairs
Coverage articles
1
4 states

TL;DR

HCPCS Q5148 is the Level II code for Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram, billed per 1 MCG. The Medicare Part B ASP payment limit for October 2026 is $1.026 per billing unit, down 0.8% from July 2026. The practitioner MUE allows up to 1500 units per date of service (MAI 3), so a full 1500-unit day is $1,539.00 at the current limit. Under OPPS it carries status indicator G in APC 0811. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. Other HCPCS codes whose descriptor names filgrastim: Q5125 (biosimilar filgrastim-ayow (Releuko) from Amneal Pharmaceuticals, LLC); Q5172 (biosimilar filgrastim-laha (Filkri) from Accord BioPharma, Inc); Q5110 (biosimilar filgrastim-aafi (Nivestym) from Pfizer Inc); Q5101 (biosimilar filgrastim-sndz (Zarxio) from Sandoz Inc); J1442 (non-biosimilar filgrastim (Neupogen) from Amgen Inc). The ASP crosswalk maps 8 NDCs to it, sold as Nypozi by Cipla USA, Inc., Tanvex BioPharma USA, Inc. 1 Medicare coverage article lists the code across 4 states, including A56748.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5148 at $1.026 per 1 MCG for October 2026, derived from manufacturer average sales price plus 6%, compared with $1.034 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q5148
QuarterPayment limitPerCoinsurance
October 2026$1.0261 MCG20%
July 2026$1.0341 MCG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 8 NDCs from 2 labelers to Q5148. Report the NDC in the claim's drug segment and bill the number of Q5148 units that equals the quantity administered divided by 1 MCG; the last column gives units per full package.

NDCs that crosswalk to Q5148
NDCDrug nameLabelerPackage sizeBilling units / package
69097-0429-67NypoziCipla USA, Inc.0.8 × 1480
69097-0429-96NypoziCipla USA, Inc.0.8 × 104800
69097-0430-67NypoziCipla USA, Inc.0.5 × 1300
69097-0430-96NypoziCipla USA, Inc.0.5 × 103000
72374-0101-01NypoziTanvex BioPharma USA, Inc.0.5 × 1300
72374-0101-10NypoziTanvex BioPharma USA, Inc.0.5 × 103000
72374-0102-01NypoziTanvex BioPharma USA, Inc.0.8 × 1480
72374-0102-10NypoziTanvex BioPharma USA, Inc.0.8 × 104800

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for Q5148. For practitioners the limit is 1500 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q5148 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services15003 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital15003 Date of Service Edit: ClinicalPrescribing Information
DME supplier15003 Date of Service Edit: ClinicalPrescribing Information

MUE for Q5148 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5148 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q5148 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q5148 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists Q5148 in their HCPCS tables, covering 4 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing Q5148
ArticleTitleContractor(s)StatesRelated LCD
A56748Billing and Coding: White Cell Colony Stimulating FactorsPalmetto GBANC SC VA WVL37176

Diagnoses Medicare contractors cover for Q5148

One billing and coding article attaches a covered diagnosis list to Q5148: 1,265 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for Q5148
ICD-10-CMDescription (FY2027)Articles covering
C00.0Malignant neoplasm of external upper lip1 of 1
C00.1Malignant neoplasm of external lower lip1 of 1
C00.2Malignant neoplasm of external lip, unspecified1 of 1
C00.3Malignant neoplasm of upper lip, inner aspect1 of 1
C00.4Malignant neoplasm of lower lip, inner aspect1 of 1
C00.5Malignant neoplasm of lip, unspecified, inner aspect1 of 1
C00.6Malignant neoplasm of commissure of lip, unspecified1 of 1
C00.8Malignant neoplasm of overlapping sites of lip1 of 1
C00.9Malignant neoplasm of lip, unspecified1 of 1
C01Malignant neoplasm of base of tongue1 of 1
C02.0Malignant neoplasm of dorsal surface of tongue1 of 1
C02.1Malignant neoplasm of border of tongue1 of 1
C02.2Malignant neoplasm of ventral surface of tongue1 of 1
C02.3Malignant neoplasm of anterior two-thirds of tongue, part unspecified1 of 1
C02.4Malignant neoplasm of lingual tonsil1 of 1
1,250 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q5148 are counted here: a group whose instructions name Q5148, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to Q5148, by article
ArticleContractorGroups that applyCovered codes for Q5148Full list
A56748Palmetto GBA11 groups apply to Q51481,265On LCD L37176

Local coverage policies that list Q5148

1 active Local Coverage Determination lists Q5148 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q5148 carries status indicator G and is assigned to APC 0811, with a published national unadjusted payment of $1.026. Status G marks pass-through drug payment, which is time-limited.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q5148 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $1.03 per 1 MCG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q5148 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q5148

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q5148

What does HCPCS code Q5148 describe?

Q5148 is defined by CMS as "Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram". Each billing unit represents 1 MCG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q5148 a CPT code?

No. Q5148 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as filgrastim-txid (Nypozi); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5148 reports the drug itself in 1 mcg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q5148 in October 2026?

The ASP-based payment limit is $1.026 per 1 MCG, with 20% beneficiary coinsurance. The July 2026 limit was $1.034. Commercial payers use their own fee schedules.

How many units of Q5148 can be billed per day?

The practitioner Medically Unlikely Edit is 1500 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to Q5148?

The October 2026 ASP crosswalk lists 8 NDCs from 2 labelers: Nypozi (Cipla USA, Inc.); Nypozi (Tanvex BioPharma USA, Inc.). For example NDC 69097-0429-67 (package size 0.8) equals 480 billing units of Q5148.

Does Q5148 have NCCI bundling edits?

No active practitioner PTP pairs list Q5148 as a column-1 or column-2 code in the v323r0 release.

Q5148 vs Q5125: what is the difference?

Both are HCPCS Level II codes whose descriptor names filgrastim. What sets Q5125 apart: biosimilar filgrastim-ayow (Releuko) from Amneal Pharmaceuticals, LLC. Q5148 is billed per 1 mcg, limit $1.026, MUE 1500; Q5125 is billed per 1 mcg, limit $0.308, MUE 1800. Report the code whose descriptor matches the product and setting in the record.

Q5148 vs Q5172: what is the difference?

Both are HCPCS Level II codes whose descriptor names filgrastim. What sets Q5172 apart: biosimilar filgrastim-laha (Filkri) from Accord BioPharma, Inc. Q5148 is billed per 1 mcg, limit $1.026, MUE 1500; Q5172 is billed per 1 mcg, OPPS rate $0.74. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention Q5148?

1 current Billing and Coding Article in the Medicare Coverage Database lists Q5148, covering 4 states: A56748 (Billing and Coding: White Cell Colony Stimulating Factors).

What diagnosis codes support Q5148?

One Medicare billing and coding article lists 1,265 covered ICD-10-CM codes for Q5148, for example C00.0 (Malignant neoplasm of external upper lip); C00.1 (Malignant neoplasm of external lower lip); C00.2 (Malignant neoplasm of external lip, unspecified); C00.3 (Malignant neoplasm of upper lip, inner aspect); C00.4 (Malignant neoplasm of lower lip, inner aspect). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.